Posted on May 28, 2016
Join us for ADAO’s 13th Annual Asbestos Awareness and Prevention Conference, “Where Knowledge and Action Unite, on April 7-9, 2017 in Washington, DC. More than 30 renowned experts and asbestos victims from ten countries will present the latest advancements in disease prevention, global advocacy, and treatment for mesothelioma and other asbestos-caused diseases.
To give you an idea of the exceptional speakers you’ll see at our upcoming conference, we are proud to share 2016 ADAO Conference Video: “CARD’s Journey: Lessons Learned,” by Brad Black.
Brad Black, PhD, MD has been the Medical Director and CEO for the Center for Asbestos and Related Disease in Libby, Montana since 2000. He has been a physician in the Libby medical community since 1977 and became the Lincoln County Health Officer in 1984. Beginning in 1999, he worked closely with Dr. Alan Whitehouse, a Spokane, WA pulmonologist, for 9 years. Since 2000, Dr. Black has had the opportunity to care for thousands of patients and this longitudinal observation of progressive pleural fibrosis has led to a clear characterization of Libby amphibole asbestos disease. CARD continues to provide asbestos health screening and care to a population with significant Libby Amphibole exposure and related diseases. In 2008 he presented at the National Institute of Health/National Cancer Institute about the progressive pleural fibrosis and mesothelioma identified in those exposed to Libby amphibole asbestos. He was instrumental in initiating research on Libby amphibole asbestos health effects. His work has expanded into research leading to an association with pulmonologists and occupational medicine specialists from multiple academic centers around the U.S. In 2010, Dr. Black became an adjunct professor at Mount Sinai School of Medicine in New York City. He has collaborated on a number of professional journal publications, and most recently he participated in a National Institute of Environmental Health Sciences working group that developed a publication on the non- neoplastic, pleural endpoints.